Live price temporarily unavailable.
Price history
XBiotech (XBIT) is a Health Care company. Latest news and coverage below.
IPO: April 15, 2015 · $19.00 offering · NASDAQ · View IPO details →
XBiotech revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $0 | $0 | $44.0M | $18.4M | $4.01M | $0 | — | — |
| Growth (year over year) | — | — | — | — | — | −58.2% | −78.2% | −100.0% | — | — |
| Gross profit | — | — | $0 | $0 | $9.45M | $12.6M | $3.36M | $0 | — | — |
| Gross margin | — | — | — | — | 21.5% | 68.4% | 83.8% | — | — | — |
| Operating income | −$52.8M | −$34.1M | −$21.0M | −$31.2M | −$18.3M | −$25.1M | −$34.5M | −$37.5M | −$42.5M | −$55.7M |
| Operating margin | — | — | — | — | −41.5% | −136.4% | −860.1% | — | — | — |
| Net income | −$52.8M | −$33.1M | −$21.1M | $668.6M | −$11.2M | −$17.4M | −$32.9M | −$24.6M | −$38.5M | −$45.5M |
| Net margin | — | — | — | — | −25.5% | −94.7% | −820.4% | — | — | — |
| EPS (diluted) | −$1.63 | −$0.95 | −$0.59 | $14.44 | −$0.36 | −$0.58 | −$1.08 | −$0.81 | −$1.26 | −$1.49 |
| Balance sheet | ||||||||||
| Cash and equivalents | $34.3M | $31.8M | $15.8M | $714.6M | $237.4M | $237.0M | $157.3M | $200.0M | $172.7M | $125.6M |
| Total assets | $67.0M | $63.0M | $44.3M | $816.9M | $353.7M | $275.2M | $246.1M | $226.6M | $199.1M | $150.1M |
| Total liabilities | $7.99M | $2.81M | $2.95M | $61.2M | $5.11M | $5.79M | $5.70M | $7.77M | $16.8M | $9.73M |
| Shareholders' equity | $59.1M | $60.2M | $41.4M | $755.6M | $348.6M | $269.4M | $240.4M | $218.8M | $182.3M | $140.3M |
| Cash flow | ||||||||||
| Operating cash flow | −$46.0M | −$33.6M | −$16.5M | −$18.3M | −$65.1M | $69.4M | −$14.8M | −$18.7M | −$31.0M | −$39.9M |
| Capital expenditure | $4.75M | $1.41M | $122.0K | $204.0K | $3.73M | $3.52M | $585.0K | $362.0K | $1.30M | $289.0K |
| Free cash flow | −$50.8M | −$35.1M | −$16.7M | −$18.5M | −$68.9M | $65.9M | −$15.4M | −$19.1M | −$32.3M | −$40.2M |
| Dividends paid | — | — | — | $0 | $0 | $75.0M | $0 | — | — | — |
| Share buybacks | — | — | — | — | — | — | $0 | $14.0K | $0 | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$7.90M | −$8.75M | −$13.6M | −$6.34M | −$6.05M | −$29.8M | −$6.27M | −$6.15M |
| Net income | −$5.01M | −$10.5M | −$10.9M | −$1.76M | −$6.01M | −$26.9M | −$5.50M | −$6.73M |
| Balance sheet | ||||||||
| Cash and equivalents | $183.1M | $172.7M | $155.9M | $152.9M | $147.4M | $125.6M | $115.5M | $109.5M |
| Total assets | $209.9M | $199.1M | $181.9M | $178.7M | $172.4M | $150.1M | $139.8M | $133.7M |
| Total liabilities | $17.7M | $16.8M | $7.15M | $5.62M | $5.34M | $9.73M | $4.82M | $5.19M |
| Shareholders' equity | $192.1M | $182.3M | $174.7M | $173.1M | $167.1M | $140.3M | $135.0M | $128.5M |
| Cash flow | ||||||||
| Operating cash flow | −$5.84M | −$6.54M | −$6.72M | −$5.99M | −$4.26M | −$23.0M | −$8.97M | −$4.51M |
| Capital expenditure | $338.0K | $84.0K | $94.0K | $51.0K | $110.0K | $34.0K | $0 | $0 |
| Free cash flow | −$6.18M | −$6.62M | −$6.81M | −$6.04M | −$4.37M | −$23.0M | −$8.97M | −$4.51M |
| Share buybacks | $0 | $0 | — | — | — | — | — | — |
From XBiotech's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About XBiotech
XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
- Headquarters
- Austin, Texas From SEC filings, Oct 2026
Recent News
No recent news mentioning XBiotech in our feed yet.
Other Health Care companies to compare with XBIT
- WAY Waystar Holding Corp
- WGS Genedx Holdings Corp Class a
- WHWK Whitehawk Therapeutics
- WVE Wave Life Sciences LTD
- XENE Xenon Pharmaceuticals Inc
- XERS Xeris Biopharma Holdings Inc
- XFOR X4 Pharmaceuticals
- XGN Exagen